Cureglip-M Tablet

Cureglip-M Tablet is a combination of two medicines that control high blood sugar levels in people with type 2 diabetes mellitus. This helps prevent serious complications of diabetes, such as kidney damage and blindness, and may also reduce your chances of having a heart attack or stroke.

Cureglip-M Tablet can be prescribed alone or together with other diabetes medications. All diabetes medicines work best when used along with a healthy diet and regular exercise. The dose you are given will depend on your condition, blood sugar levels, and what other medicines you are taking. Taking it with meals helps reduce the chances of developing an upset stomach. You should take it regularly, at the same time each day, to get the most benefit, and you should not stop unless your doctor recommends it. It controls your blood sugar levels and helps prevent serious complications in the future. It is important to stay on the diet and exercise program recommended by your doctor while taking this medicine. Your lifestyle plays a big part in controlling diabetes.

The most common side effects of taking this medicine include nausea, headache, and gastroesophageal reflux disease. Low blood sugar level (hypoglycemia) is also a possible side effect if you are also taking other diabetes medicines like insulin or sulfonylurea, so you need to know how to recognize and deal with it.

This medicine is not suitable for everyone. Before taking it, you should let your doctor know if you have ever had kidney, liver, or heart disease; problems with your pancreas; or if you drink a lot of alcohol. Pregnant or breastfeeding women should also consult their doctor before taking this medicine. Some other medicines can affect this one, so tell your doctor about all the medicines you are taking to make sure Cureglip-M Tablet is safe. You should try to avoid drinking alcohol, as it lowers blood glucose. Your doctor will check your kidney function and blood sugar levels before and during treatment.

Treatment of Type 2 diabetes mellitus

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Cureglip-M Tablet is to be taken with food.

Cureglip-M Tablet is a combination of two antidiabetic medicines: metformin and vildagliptin. Metformin is an anti-diabetic medication (biguanide). It works by lowering glucose production in the liver, delaying glucose absorption from the intestines, and increasing the body’s sensitivity to insulin. Vildagliptin is a DPP-4 inhibitor that works by increasing the release of insulin from the pancreas and decreasing the hormones that raise blood sugar levels. This reduces both fasting and post-meal sugar levels. Together, they provide better control of blood sugar.

Q: What if you forget to take Cureglip-M Tablet?
A: If you miss a dose of Cureglip-M Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.

Take it in addition to regular exercise and a healthy diet to lower levels of blood sugar.

Take it with food to lower your chance of having an upset stomach.

Inform your doctor about your diabetes treatment if you are due to have surgery under a general anesthetic.

Tell your doctor immediately if you experience any deep or rapid breathing, persistent nausea, vomiting, and stomach pain, as Cureglip-M Tablet may cause a rare but serious condition called lactic acidosis, which is an excess of lactic acid in the blood.

Your doctor may check your kidney and liver function before starting treatment and regularly thereafter. Inform your doctor if you develop symptoms such as abdominal pain, fatigue, loss of appetite, darkened urine, or yellowing of the eyes or skin (jaundice).

Q. What is Cureglip-M Tablet?

Cureglip-M Tablet is a combination of two anti-diabetic drugs: metformin and vildagliptin. Metformin is an anti-diabetic medicine and belongs to the class of biguanides. It lowers the glucose production in the liver, delays glucose absorption from the intestines, and increases the body’s sensitivity to insulin. Vildagliptin inhibits the enzyme DPP4 and increases the release of insulin from the pancreas. This combination is not advised for patients below 18 years of age.

Q. Is it safe to use Cureglip-M Tablet?

Yes, it is safe to use Cureglip-M Tablet if you take it for the prescribed duration and according to the dosage advised by the doctor. However, despite taking the prescribed dosage, you might experience common side effects like nausea, diarrhea, vomiting, stomach upset, headache, nasal congestion, sore throat, respiratory tract infection, or hypoglycemia (low blood sugar level) in combination with insulin or sulfonylurea. Inform your doctor if you experience any persistent problems while taking this medicine.

Q. Can the use of Cureglip-M Tablet cause hypoglycemia?

The use of Cureglip-M Tablet does not usually cause hypoglycemia (low blood sugar level) alone. But it could occur if there is insufficient supplementation of calories while taking this medicine. Symptoms of hypoglycemia include nausea, headache, irritability, hunger, sweating, dizziness, fast heart rate, and feeling anxious or shaky. The symptoms are more likely to be noticed if you miss or delay your food, drink alcohol, over-exercise, or take any other antidiabetic medicine along with it. So, regular monitoring of blood sugar levels is important. It is recommended to always carry glucose tablets, honey, or fruit juice with you.

Q. Can the use of Cureglip-M Tablet cause nausea and vomiting?

Yes, the use of Cureglip-M Tablet can cause nausea and vomiting. In case of vomiting, drink plenty of water or other fluids by taking small, frequent sips. Talk to your doctor if vomiting persists and you notice signs of dehydration, like dark-colored and strong-smelling urine and a low frequency of urination. Do not take any other medicine without speaking to a doctor.

Q. Are there any specific contraindications associated with the use of Cureglip-M Tablet?

The use of Cureglip-M Tablet should be avoided in patients with known allergies to any of the components or excipients of this medicine. The use of this medicine is also considered to be harmful to patients with severe kidney impairment, liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.

Q. Can the use of Cureglip-M Tablet cause lactic acidosis?

Yes, the use of Cureglip-M Tablet can lead to lactic acidosis. It is a medical emergency that is caused by increased levels of lactic acid in the blood. It is also known as MALA (metformin-associated lactic acidosis). It is a very rare side effect associated with the use of metformin, and therefore, it is avoided in patients with underlying kidney disease, elderly patients, or those who take large amounts of alcohol. Symptoms of lactic acidosis may include muscle pain or weakness, dizziness, tiredness, the feeling of cold in arms and legs, difficulty in breathing, nausea, vomiting, stomach pain, or slow heart rate. If you have these symptoms, stop taking Cureglip-M Tablet and immediately consult your doctor.

Q. Can the use of Cureglip-M Tablet lead to vitamin B12 deficiency?

Yes, the use of Cureglip-M Tablet can cause vitamin B12 deficiency with long-term use. It interferes with the absorption of vitamin B12 in the stomach. If untreated, it may cause anemia and nerve problems.

Q. What is the storage condition for the Cureglip-M Tablet?

Keep this medicine in the container or the pack it came in, tightly closed. Store it according to the instructions mentioned on the pack or label. Dispose of the unused medicine. Make sure it is not consumed by pets, children, and other people.

In Treatment of Type 2 diabetes mellitus

Cureglip-M Tablet is a combination of two medicines that work together in different ways to lower your blood glucose levels. Lowering blood glucose levels is an essential part of managing diabetes. If you can control your blood glucose level, your risk of getting any of the serious complications of diabetes such as kidney damage, eye damage, nerve problems, and loss of limbs is also lowered. Additionally, proper control of diabetes can also reduce the risk of heart disease and stroke. Taking this medicine regularly along with proper diet and exercise will help you live a normal, healthy life. You should keep using this medicine for as long as it is prescribed because it is protecting your future health.

Trembling

Headache

Dizziness

Nausea

Gastro-esophageal reflux disease

Upper respiratory tract infection

Alcohol:UNSAFE

It is unsafe to consume alcohol with Cureglip-M Tablet.

Pregnancy:CONSULT YOUR DOCTOR

Cureglip-M Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.

Breast feeding:CONSULT YOUR DOCTOR

Cureglip-M Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.

Driving:CAUTION

Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.

Kidney:CAUTION

Cureglip-M Tablet should be used with caution in patients with kidney disease. Dose adjustment of Cureglip-M Tablet may be needed. Please consult your doctor.

Liver:UNSAFE

Cureglip-M Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.

Vildagliptin/metformin hydrochloride [EMC SmPC]. Nuremberg, Germany: Novartis Pharma GmbH; 2018. [Accessed 22 Jan. 2019] (online) Available from: View
Metformin hydrochloride [FDA Label]. Princeton, New Jersey: Bristol-Myers Squibb Company; 2008. [Accessed 08 Apr. 2019] (online) Available from: View
Vildagliptin/Metformin (Vilact-M) [Product Monograph]. Mumbai, Maharashtra: Panacea Biotec Limited; 2019. [Accessed 20 Oct. 2021] (online) Available from: View
Vildagliptin/Metformin hydrochloride [Summary of Product Characteristics]. Barcelona, Spain: Accord Healthcare S.L.U.; 2022. [Accessed 27 Mar. 2025] (online) Available from: View